Showing results (51-60 of 66) with videos related to

Sort By:
Pageof 7
Blood Advances|April 9, 2024
Immunoglobulin replacement vs prophylactic antibiotics for hypogammaglobulinemia secondary to hematological malignancyZoe K McQuilten, Robert Weinkove, Le Thi Phuong Thao, et al.
Immunology and Cell Biology|September 18, 2023
Artificial intelligence takes center stage: exploring the capabilities and implications of ChatGPT and other AI-assisted technologies in scientific research and educationJessica G Borger, Ashley P Ng, Holly Anderton, et al.
Internal Medicine Journal|August 8, 2017
Bisphosphonate guidelines for treatment and prevention of myeloma bone diseaseOi Lin Lee, Noemi Horvath, Cindy Lee, et al.
Ejhaem|April 18, 2024
Poor outcomes for trial-ineligible patients receiving polatuzumab for relapsed/refractory diffuse large B-cell lymphoma in routine care: An Australian Lymphoma and Related Diseases Registry projectBriony Shaw, Eliza Chung, Cameron Wellard, et al.
Blood Advances|March 14, 2024
Economic evaluation: immunoglobulin vs prophylactic antibiotics in hypogammaglobulinemia and hematological malignanciesSara Carrillo de Albornoz, Alisa M Higgins, Dennis Petrie, et al.
Best Practice & Research. Clinical Haematology|December 13, 2023
The Australian Aplastic Anaemia and other Bone Marrow Failure Syndromes RegistryLucy C Fox, Zoe K McQuilten, Frank Firkin, et al.
Internal Medicine Journal|January 12, 2017
Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory GroupDipti Talaulikar, Constantine S Tam, Douglas Joshua, et al.
Blood Advances|April 17, 2023
Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphomaNancy L Bartlett, Sarit Assouline, Pratyush Giri, et al.
Internal Medicine Journal|October 19, 2021
Imaging of patients with multiple myeloma and associated plasma cell disorders: consensus practice statement by the Medical Scientific Advisory Group to Myeloma AustraliaKatherine Creeper, Bradley Augustson, Kieran Kusel, et al.
Hematological Oncology|April 16, 2019
A multicenter retrospective comparison of induction chemoimmunotherapy regimens on outcomes in transplant-eligible patients with previously untreated mantle cell lymphomaZi Yun Ng, Mark Bishton, David Ritchie, et al.
Pageof 7